Ardena says the investment is driven by business growth, capacity needs and its ambition to become a leading mid-sized CDMO. In partnership with GHO Capital, contract development manufacturing organization (CDMO) Ardena has invested $35 million to expand its European operations in Belgium, Sweden, and the Netherlands to ensure the firm can offer end-to-end solutions. “All expansion work is expected to be complete by Q1 in 2023,” Gerjan Kemperman COO at Ardena told BioProcess Insider. The firm will expand its drug product…

SP has opened a large-scale facility in Barcelona, Spain doubling its global manufacturing capacity for fill-finish services. SP Scientific Products (SP) said that in order to meet the increasing demand for fill-finish and lyophilization (freeze dryer) equipment, it has more than doubled its global manufacturing capacity. The new 4,000 meter Barcelona plant will be equipped to offer fill-finish services and SP is also upping its production headcount and restructuring its manufacturing processes. “This is a multi-million-euro investment including the new…

Recipharm has signed a Memorandum of Understanding for the fill-finish of biotherapeutics and vaccines in Morocco.    Contract development manufacturing organization (CDMO) Recipharm signed the Memorandum of Understanding (MOU) with the King of Morocco, various Moroccan banks, and the Moroccan Government. As part of the MOU, approximately $500 million will be invested by the Moroccan government and others over the next five years to secure capacity and capability for the production of vaccines and biotherapeutics in Morocco. Recipharm will operate…

Rentschler will expand production capacity at its Laupheim, Germany facility to support the increasing demand for complex antibodies. A report published by vfa bio and Boston Consulting Group assessing the state of biotech in Germany revealed the country is falling behind in production capacity when compared globally to others.  to other countries. “While companies in the US, South Korea, Ireland, and Switzerland have expanded their production facilities in the last three years, there has been no growth at all in…

Lonza says the expansion of its high potency API facility in Nansha, China will help support growing demand for ADC production. Swiss contract development manufacturing organization (CDMO) Lonza will add three 1,000 L GMP trains, including development laboratories with the capacity to produce small scale batches of highly potent APIs (HPAPIs). The expanded site will also boast six 1,000 L small molecule reactors, four 1,500L vessels, and isolation equipment adding capacity for a smooth transition between early-phase and large-scale commercial…

Viralgen has opened an $83 million AAV production site in San Sebastian, the first gene therapy production facility in Spain. Contract development and manufacturing organization (CDMO) Viralgen said in November 2019 it would be constructing Spain’s first commercial gene therapy production site at the Miramon Technology Park in San Sebastian to add capacity for gene therapy manufacturing services. The president of the Basque Government in Spain, Iñigo Urkullu and Pedro Duque, Minister of Science and Innovation of the Spanish government opened the facility…